SIG | Lead Contact |
AI/ML | sam.hadlington@plus-project.co.uk |
AIMS | martin.brown@ppd.com |
Benefit Risk | shahrul.mt-isa@msd.com; marcoboeri@openhealthgroup.com |
Biomarkers | nicole_2.kraemer@boehringer-ingelheim.com; guillaume.desachy@pierre-fabre.com |
Causal Inference | sroels4@its.jnj.com; kelly.vanlancker@ugent.be |
CMC | kevin.r.lief@gsk.com; Beate Presser |
CSM/QTL | timothy.e.rolfe@gsk.com; susan.talbot@amgen.com |
Data Science | julia.chernova@cytel.com; Domingo
Salazar |
Historical Data | nicky.x.best@gsk.com; simon.wandel@novartis.com |
HTA | lara.wolfson@msd.com; Anders Gorst-Rasmussen (htasig@psiweb.org) |
Launch & Lifecycle | jenny.devenport@roche.com; yulia.dyachkova@merckgroup.com |
Neuroscience-Estimands | paul.delmar@roche.com |
Oncology Estimands | Oncology estimand working group |
Openstatsware | alessandro.gasparini@reddooranalytics.se; daniel.sabanes_bove@rconis.com |
Patient Focused Drug Development (PFDD) | rachael.lawrance@adelphivalues.com; konstantina.skaltsa@iqvia.com |
Pre-Clinical | eloisa.i.brook@gsk.com |
Quantitative Decision Making | tguerin@theravance.com; alex.l.carlton@gsk.com |
Randomisation | johannes.krisam@boehringer-ingelheim.com; annika.scheffold@boehringer-ingelheim.com |
Real World Data (RWD) | Josephine.Wolfram@astellas.com; rima.izem@novartis.com |
Regulatory | JHXW@novonordisk.com; christoph.gerlinger@bayer.com |
Small Populations | tal.x.otiker@gsk.com; aysun.cetinyurek-yavuz@radboudumc.nl |
Treatment Effect Heterogeneity | david.j.svensson@astrazeneca.com |
Vaccines | fabian.s.tibaldi@gsk.com |
Visualisation | kirschbodo@gmail.com |